{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T17:51:57Z","timestamp":1782409917695,"version":"3.54.5"},"reference-count":39,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.m2021.0022","type":"journal-article","created":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T17:05:41Z","timestamp":1619543141000},"source":"Crossref","is-referenced-by-count":6,"title":["Follicular Lymphoma\u2014Diagnosis, Treatment, and Follow-Up"],"prefix":"10.3238","author":[{"given":"Anna","family":"Zoellner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Herfarth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Herold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfram","family":"Klapper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Skoetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Hiddemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2021,5,7]]},"reference":[{"key":"10.3238\/arztebl.m2021.0022_ref1","unstructured":"Zentrum f\u00fcr Krebsregisterdaten und Gesellschaft der epidemiologischen Krebsregister in Deutschland: Krebs in Deutschland f\u00fcr 2015\/2016. Robert Koch-Institut, Berlin 2019."},{"key":"10.3238\/arztebl.m2021.0022_ref2","doi-asserted-by":"crossref","unstructured":"Schmidt C, Fingerle-Rowson G, Boehme A, et al.: Changes in the diagnosis and treatment of patients with low grade lymphoma in Germany: years 2006\u20132009. Leuk Lymphoma 2015; 56: 694\u2013702","DOI":"10.3109\/10428194.2014.928935"},{"key":"10.3238\/arztebl.m2021.0022_ref3","doi-asserted-by":"crossref","unstructured":"Hiddemann W, Cheson BC: How we manage follicular lymphoma. Leukemia 2014; 28:1388\u201395","DOI":"10.1038\/leu.2014.91"},{"key":"10.3238\/arztebl.m2021.0022_ref4","doi-asserted-by":"crossref","unstructured":"Wohrer S, Jaeger U, Kletter K, et al.: 18F-fluoro-deoxy-glucose positron emissiontomography (18F-FDG-PET) visualizes follicular lymphoma irrespective of grading. Ann Oncol 2006; 17: 780\u20134","DOI":"10.1093\/annonc\/mdl014"},{"key":"10.3238\/arztebl.m2021.0022_ref5","doi-asserted-by":"crossref","unstructured":"Wirth A, Foo M, Seymour JF, Macmanus MP, Hicks JR: Impact of [18f] fluorodeoxyglucose positron emission tomography on staging and management of early-stage follicular non-hodgkin lymphoma. Int J Radiat Oncol Biol Phys 2008; 71: 213\u20139","DOI":"10.1016\/j.ijrobp.2007.09.051"},{"key":"10.3238\/arztebl.m2021.0022_ref6","doi-asserted-by":"crossref","unstructured":"Metser U, Dudebout J, Baetz T, et al.: [(18) F]-FDG PET\/CT in the staging and management of indolent lymphoma: a prospective multicenter PET registry study. Cancer 2017; 123: 2860\u20136","DOI":"10.1002\/cncr.30672"},{"key":"10.3238\/arztebl.m2021.0022_ref7","unstructured":"Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M: Report of the committee on Hodgkin\u2018s disease staging classification. Cancer Res 1971; 31: 1860\u20131."},{"key":"10.3238\/arztebl.m2021.0022_ref8","doi-asserted-by":"crossref","unstructured":"Lowry L, Smith P, Qian W, et al.: Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. Radiother Oncol 2011; 100: 86\u201392","DOI":"10.1016\/j.radonc.2011.05.013"},{"key":"10.3238\/arztebl.m2021.0022_ref9","doi-asserted-by":"crossref","unstructured":"Stuschke M, Hoederath A, Sack H, et al.: Extended field and total central lymphatic radiotherapy in the treatment of early stage lymph node centroblastic-centrocytic lymphomas: results of a prospective multicenter study. Study Group NHL-fr\u00fche Stadien. Cancer 1997; 80: 2273\u201384","DOI":"10.1002\/(SICI)1097-0142(19971215)80:12<2273::AID-CNCR9>3.0.CO;2-V"},{"key":"10.3238\/arztebl.m2021.0022_ref10","doi-asserted-by":"crossref","unstructured":"Mac Manus MP, Hoppe RT: Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol 1996; 14: 1282\u201390","DOI":"10.1200\/JCO.1996.14.4.1282"},{"key":"10.3238\/arztebl.m2021.0022_ref11","unstructured":"Engelhard M, Unterhalt M, Hansmann ML, Stuschke M: Follicular lymphoma: final results of the randomized evaluation of curative radiotherapy in limited stage nodal disease. Strahlenther Onkol 2013; 189 (Suppl 1): 36."},{"key":"10.3238\/arztebl.m2021.0022_ref12","doi-asserted-by":"crossref","unstructured":"Friedberg JW, Byrtek M, Link BK, et al.: Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study. J Clin Oncol 2012; 30: 3368\u201375","DOI":"10.1200\/JCO.2011.40.6546"},{"key":"10.3238\/arztebl.m2021.0022_ref13","doi-asserted-by":"crossref","unstructured":"MacManus M, Fisher R, Roos D, et al.: Randomized trial of systemic therapy after involved-field radiotherapy in patients with early-stage follicular lymphoma: TROG 99.03. J Clin Oncol 2018; 36: 2918\u201325","DOI":"10.1200\/JCO.2018.77.9892"},{"key":"10.3238\/arztebl.m2021.0022_ref14","doi-asserted-by":"crossref","unstructured":"Herfarth K, Borchmann P, Schnaidt S, et al.: Rituximab with involved field irradiation for early-stage nodal follicular lymphoma: results of the MIR study. Hemasphere 2018; 2: e160","DOI":"10.1097\/HS9.0000000000000160"},{"key":"10.3238\/arztebl.m2021.0022_ref15","doi-asserted-by":"crossref","unstructured":"Brice P, Bastion Y, Lepage E, et al.: Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d\u2018\u00c9tude des Lymphomes Folliculaires. Groupe d\u2018\u00c9tude des Lymphomes de l\u2018Adulte. J Clin Oncol 1997; 15: 1110\u20137","DOI":"10.1200\/JCO.1997.15.3.1110"},{"key":"10.3238\/arztebl.m2021.0022_ref16","doi-asserted-by":"crossref","unstructured":"Dreyling M, Ghielmini M, Rule S, Salles G, Vitolo U, Ladetto M.: Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016; 27 (Suppl 5): v83\u201390","DOI":"10.1093\/annonc\/mdw400"},{"key":"10.3238\/arztebl.m2021.0022_ref17","doi-asserted-by":"crossref","unstructured":"Ardeshna KM, Qian W, Smith P, et al.: Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. Lancet Oncol 2014; 15: 424\u201335","DOI":"10.1016\/S1470-2045(14)70027-0"},{"key":"10.3238\/arztebl.m2021.0022_ref18","doi-asserted-by":"crossref","unstructured":"Nastoupil LJ, Sinha R, Byrtek M, et al.: Outcomes following watchful waiting for stage II-IV follicular lymphoma patients in the modern era. Br J Haematol 2016; 172: 724\u201334","DOI":"10.1111\/bjh.13895"},{"key":"10.3238\/arztebl.m2021.0022_ref19","doi-asserted-by":"crossref","unstructured":"Hiddemann W, Kneba M, Dreyling M, et al.: Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106: 3725\u201332","DOI":"10.1182\/blood-2005-01-0016"},{"key":"10.3238\/arztebl.m2021.0022_ref20","doi-asserted-by":"crossref","unstructured":"Herold M, Haas A, Srock S, et al.: Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 2007; 25: 1986\u201392","DOI":"10.1200\/JCO.2006.06.4618"},{"key":"10.3238\/arztebl.m2021.0022_ref21","doi-asserted-by":"crossref","unstructured":"Marcus R, Imrie K, Solal-Celigny P, et al.: Phase III study of RCVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008; 26: 4579\u201386","DOI":"10.1200\/JCO.2007.13.5376"},{"key":"10.3238\/arztebl.m2021.0022_ref22","doi-asserted-by":"crossref","unstructured":"Salles G, Mounier N, de Guibert S, et al.: Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood 2008; 112: 4824\u201331","DOI":"10.1182\/blood-2008-04-153189"},{"key":"10.3238\/arztebl.m2021.0022_ref23","doi-asserted-by":"crossref","unstructured":"Hiddemann W, Barbui AM, Canales MA, et al.: Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: influence of chemotherapy on efficacy and safety. J Clin Oncol 2018; 36: 2395\u2013404","DOI":"10.1200\/JCO.2017.76.8960"},{"key":"10.3238\/arztebl.m2021.0022_ref24","doi-asserted-by":"crossref","unstructured":"Marcus R, Davies A, Ando K, et al.: Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med 2017; 377: 1331\u201344","DOI":"10.1056\/NEJMoa1614598"},{"key":"10.3238\/arztebl.m2021.0022_ref25","doi-asserted-by":"crossref","unstructured":"Salles G, Seymour JF, Offner F, et al.: Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011; 377: 42\u201351","DOI":"10.1016\/S0140-6736(10)62175-7"},{"key":"10.3238\/arztebl.m2021.0022_ref26","doi-asserted-by":"crossref","unstructured":"Bachy E, Seymour JF, Feugier P, et al.: Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study. J Clin Oncol 2019; 37: 2815\u201324","DOI":"10.1200\/JCO.19.01073"},{"key":"10.3238\/arztebl.m2021.0022_ref27","doi-asserted-by":"crossref","unstructured":"Vidal L, Gafter-Gvili A, Salles G, et al.: Rituximab maintenance improves overall survival of patients with follicular lymphoma\u2014individual patient data meta-analysis. Eur J Cancer 2017; 76: 216\u201325","DOI":"10.1016\/j.ejca.2017.01.021"},{"key":"10.3238\/arztebl.m2021.0022_ref28","doi-asserted-by":"crossref","unstructured":"Matsumoto K, Takayama N, Aisa Y, et al.: A phase II study of bendamustine plus rituximab in Japanese patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma previously treated with rituximab: BRB study. Int J Hematol 2015; 101: 554\u201362","DOI":"10.1007\/s12185-015-1767-3"},{"key":"10.3238\/arztebl.m2021.0022_ref29","doi-asserted-by":"crossref","unstructured":"Weide R, Feiten S, Friesenhahn V, et al.: Retreatment with bendamustine-containing regimens in patients with relapsed\/refractory chronic lymphocytic leukemia and indolent B-cell lymphomas achieves high response rates and some long lasting remissions. Leuk Lymphoma 2013; 54: 1640\u20136","DOI":"10.3109\/10428194.2012.747679"},{"key":"10.3238\/arztebl.m2021.0022_ref30","doi-asserted-by":"crossref","unstructured":"Cheson BD, Chua N, Mayer J, et al.: Overall survival benefit in patients with rituximab-refractory indolent non-Hodgkin lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN study. J Clin Oncol 2018; 36: 2259\u201366","DOI":"10.1200\/JCO.2017.76.3656"},{"key":"10.3238\/arztebl.m2021.0022_ref31","doi-asserted-by":"crossref","unstructured":"Casulo C, Friedberg JW, Ahn KW, et al.: Autologous transplantation in follicular lymphoma with early therapy failure: a National Lymphocare Study and Center for International Blood and Marrow Transplant Research analysis: Biol Blood Marrow Transplant 2018; 24: 1163\u201371.","DOI":"10.1016\/j.bbmt.2017.12.771"},{"key":"10.3238\/arztebl.m2021.0022_ref32","doi-asserted-by":"crossref","unstructured":"Jurinovic V, Metzner B, Pfreundschuh M, et al.: Autologous stem cell transplantation for patients with early progression of folicular lymphoma: a follow-up study of 2 randomized trials from the German Low Grade Lymphoma Study Group. Biol Blood Marrow Transplant 2018; 24: 1172\u20139","DOI":"10.1016\/j.bbmt.2018.03.022"},{"key":"10.3238\/arztebl.m2021.0022_ref33","doi-asserted-by":"crossref","unstructured":"Matasar MJ, Luminari S, Barr PM, et al.: Follicular lymphoma: recent and emerging therapies, treatment strategies and remaining unmet needs. Oncologist 2019; 24: e1236\u201350","DOI":"10.1634\/theoncologist.2019-0138"},{"key":"10.3238\/arztebl.m2021.0022_ref34","doi-asserted-by":"crossref","unstructured":"Batlevi CL, Sha F, Alperovich A, et al.: Follicular lymphoma in the modern era: survival, treatment outcomes and identification of high-risk subgroups. Blood Cancer J 2020; 10: 74","DOI":"10.1038\/s41408-020-00340-z"},{"key":"10.3238\/arztebl.m2021.0022_ref35","doi-asserted-by":"crossref","unstructured":"H\u00fcbel K, Ghielmini M, Ladetto M, Gopal AK: Controversies in the treatment of follicular lymphoma. Hemasphere 2020; 4: e317","DOI":"10.1097\/HS9.0000000000000317"},{"key":"10.3238\/arztebl.m2021.0022_ref36","doi-asserted-by":"crossref","unstructured":"Lenz G, Dreyling M, Schiegnitz E, et al.: Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group. J Clin Oncol 2004; 22: 4926\u201333","DOI":"10.1200\/JCO.2004.06.016"},{"key":"10.3238\/arztebl.m2021.0022_ref37","doi-asserted-by":"crossref","unstructured":"Schaaf M, Reiser M, Borchmann P, Engert A, Skoetz N: High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults. Cochrane Database Syst Rev 2012; 1: CD007678","DOI":"10.1002\/14651858.CD007678.pub2"},{"key":"10.3238\/arztebl.m2021.0022_ref38","doi-asserted-by":"crossref","unstructured":"Valcovici M, Andrica F, Serban C, Dragan S: Cardiotoxicity of anthracycline therapy: current perspectives. Arch Med Sci 2016; 12: 428\u201335","DOI":"10.5114\/aoms.2016.59270"},{"key":"10.3238\/arztebl.m2021.0022_ref39","doi-asserted-by":"crossref","unstructured":"Moser EC, Noordijk EM, van Leeuwen FE, et al.: Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma. Blood 2006; 107: 2912\u20139","DOI":"10.1182\/blood-2005-08-3392"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2021.0022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T20:58:15Z","timestamp":1698958695000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2021.0022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,7]]},"references-count":39,"URL":"https:\/\/doi.org\/10.3238\/arztebl.m2021.0022","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,7]]}}}